PMPRB report finds high-priced specialty meds dominating new drug landscape
New drugs launched since 2009 accounted for nearly one quarter of brand-name drug sales in Canada by 2016, according to a report from the Patented Medicine Prices Review Board (PMPRB). As well, in line with trends observed from 2009 to 2014, the